Warner-Lambert/Glaxo
This article was originally published in The Tan Sheet
Executive Summary
Finalize joint venture to develop, seek approval and market over-the-counter versions of Glaxo prescription drugs, initially focusing on an Rx-to-OTC switch of Zantac (ranitidine). Warner- Lambert and Glaxo announced a letter of intent agreement to form the joint venture in July ("The Tan Sheet" Aug. 2, p. 4). The entity will be managed by a soon-to-be-announced committee of representatives from each company, with day-to-day operations being handled by Warner-Lambert. Warner-Welcome, a separate joint venture formed with Burroughs Wellcome, will market OTC products arising from the GIaxo/W-L deal.